The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon α2b

Cancer Immunology Immunotherapy

Volumn 43, Issue 2, 1996, Pages 94-102

  Tsavaris, N ^a   Baxevanis, C ^b   Kosmidis, P ^c   Papamichael, M ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b Hellenic Anticancer Institute   (Greece)

^c METAXA CANCER HOSPITAL   (Greece)

Author keywords

colorectal cancer; immune changes; interferon 2b; melanoma; renal cell carcinoma

Indexed keywords

FOLINIC ACID; INTERLEUKIN 1; INTERLEUKIN 2 RECEPTOR; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; KIDNEY CANCER; MALE; MELANOMA; MIXED LYMPHOCYTE REACTION; MONOCYTE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; COLORECTAL NEOPLASMS; EVALUATION STUDIES; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON ALFA-2B; KIDNEY NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS;

EID: 0029851566     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050308     Document Type: Article

References (35)

1. Anastasopoulos E, Reclos G, Baxevanis C, Panagiotopoulos N, Fotiou S, Missitzis I, Karydas E, Papamichael M (1992) Monocyte disorders associated with T cells defects in cancer patients with solid tumors. Anticancer Res 12: 489-494
2. Bacouche O, Koff C, Brown D, Lachman L (1987) Interleukin-1 release by human monocytes treated with liposome-encapsulated lipopolysaccharide. J Immunol 139: 1120-1126
3. Baxevanis C, Nagy Z, Klein J (1981) A novel type of T-T cell interaction removes the requirement for I-B region on the H-2 complex. Proc Natl Acad Sci USA 78: 3809-3813
4. Baxevanis C, Reclos G, Sfagos C, Doufexis E, Papageorgiou C, Papamichael M (1987) Multiple sclerosis. I. Monocytes stimulatory defect in mixed lymphocyte reaction associated with clinical disease activity. Clin Exp Immunol 67: 362-371
5. Baxevanis C, Reclos G, Paneerselvan M, Papamichael M (1988) Enhancement of human T-lymphocyte functions by prothymosin a, I. Augmentation of mixed lymphocyte culture reactions and soluble protein induced proliferative responses. Immunopharmacology 15: 73-81
6. Baxevanis C, Reclos G, Arsenis P, Anastasopoulos E, Katsigiannis A, Matikas N, Lymberi P, Papamichael M (1989) Decreased expression of HLA-DR antigens on monocytes in patients with multiple sclerosis. J Neuroimmunol 22: 177-183
7. Baxevanis C, Reclos G, Papamichael M (1990) Decreased HLA-DR antigen expression on monocytes causes impaired suppressor cell activity in multiple sclerosis. J Immunol 144: 4166
8. Bishop G, Glorioso J, Schwartz S (1983) Role of interferon in human natural killer activity against target cells infected with HSV-1. J Immunol 131: 1849-1855
9. Bonnem EM (1987) Alfa interferon combinations with other antineoplastic modalities. Semin Oncol 14: 48-60
10. Buraid A, Todd M (1989) Therapeutic options in renal cell carcinoma. Semin Oncol 16: 12-19
11. Bztein M, Steeg P, Johnson H, Oppenheim J (1984) Regulation of human peripheral blood monocyte DR antigen expression in vitro by lymphokines and recombinant interferons. J Clin Invest 73: 556-562
12. Chouaid S, Welte K, Dupont B (1985) Differential effect of anti-β2-microglobulin on IL-2 production in the primary mixed lymphocyte culture reaction. J Immunol 134: 940-948
13. Dixon WJ, Massey FJ Jr (1983) Introduction to statistical analysis. 4th edn. McGraw-Hill, New York
14. 13a. Gillis 1978
15. Hawkins M, Horning S, Konrad S (1985) Phase I evaluation of a synthetic mutant of interferon™. Cancer Res 45: 5914-5920
16. Inghirami G, Djien J, Balow J, Tsokos G (1985) Enhancement of human allogeneic cytotoxic responses by interferons. J Immunopharmacol 7: 403-412
17. Itoh K, Inone M, Katsaoka S, Kumagai K (1980) Differential effect of interferon expression of IgG and IGM-Fc receptors on human lymphocytes. J Immunol 124: 2589-2595
18. Kaplan EL, Meier P (1958) Non parametric estimation for incomplete observations. J Am Statist Assoc 53: 457-481
19. Kirkwood J, Ernstoff M (1984) Interferons in the treatment of human cancer. J Clin Oncol 2: 336-345
20. Klein J, Nagy Z (1982) MCH restriction and Ir genes. Adv Cancer Res 37: 233-271
21. Kosmidis P, Baxevanis K, Tsavaris N, Papanastasiou M, Anastasopoulos E, Bacoyiannis Ch, Mylonakis N, Karvounis N, Bafaloukos D, Karabelis A, Papamichael M (1992) The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon Alfa-2b. J Clin Oncol 10: 1153-1159
22. Machin D, Campbell MJ (1987) Statistical tables for the design of clinical trials. Blackwell, Oxford, pp 79-83
23. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50: 163-170
24. Palacios R (1982) Mechanism of T-cell activation. Role and functional relationship of HLA-DR antigens and interleukins. Immunol Rev 63: 42-85
25. Pfeffer LM, Tamm I (1984) Interferon inhibition of thymidine incorporation into DNA through effects on thymidine transport and uptake. J Cell Physiol 121: 431-437
26. Rhodes J, Stokes P (1982) Interferon induced changes in the monocyte membrane: inhibition by retinol and retinoic acid. Immunology 45: 531-542
27. Rhodes J, Jones D, Blechen N (1983) Increased expression of human monocyte HLA-DR antigens and FCγ receptors in response to human interferon in vivo. Clin Exp Immunol 53: 739-747
28. Rodriguez M, Prinz W, Sibbitt W, Bankhurst A, Williams RD Jr (1983) α-Interferon increases immunoglobulin production in cultured human mononuclear leukocytes. J Immunol 130: 1215-1220
29. Shirakawa F, Yamashita V, Sutuki H (1985) Decrease in HLA-DR positive monocytes in patients with systemic lupus erythematosus. J Immunol 134: 3560-3566
30. Smith J, Knowlton K, Koons L (1977) Immunologic studies in chronic lymphocytic leukemia: defective stimulation of T-cell proliferation in autologous mixed lymphocyte culture. J Natl Cancer Inst 58: 579-586
31. Spear G, Paulnock D, Jordan R, Meltaer D, Merriff J, Borden E (1987) Enhancement of monocyte class I and II histocompatibility antigen expression in man in vivo by ™-interferon. Clin Exp Immunol 69: 107-114
32. Tsavaris N, Mylonakis N, Bacoyiannis Ch, Tsoutsos H, Karabelis A, Kosmidis P (1993) Treatment of renal cell carcinoma with escalating doses of α-interferon. Chemotherapy 39: 361-365
33. Tsavaris N, Baxevanis K, Kosmidis P, Papamichael M (1995) The prognostic significance of immune changes in patients with renal cancer and melanoma treated with interferon α2b. Tumor Biol 16: 365-373
34. Uchida A, Miksche M (1982) Autologous mixed lymphocyte reaction in the peripheral blood and pleural effusions of cancer patients. J Clin Invest 70: 98-107
35. Uchida A, Micksche M (1981) Concavalin-A inducible suppressor cells in pleural effusions and peripheral blood of cancer patients. Cancer Immunol Immunother 10: 203-210